Patents by Inventor Patrick VIGNEAULT

Patrick VIGNEAULT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered stem cells and cellular products produced and secreted by such cells, methods of preparing, and uses thereof
    Patent number: 11795434
    Abstract: There is disclosed a cardiac explant-derived stem cell (EDC), the cell comprising a gene encoding an intermediate-conductance Ca2+-activated K+ channel, and wherein the gene causes an overexpression of the intermediate-conductance Ca2+-activated K+ channel, and methods of producing same. There is also disclosed a method of producing engineered EDCs having a modulated bioelectric property, the method comprising: obtaining EDCs; introducing a KCNN4 gene into the EDCs to increase the expression of KCa3.1 channels, to produce engineered EDCs. There is also disclosed a composition for treating or ameliorating a damaged myocardium in a subject, the composition comprising extracellular vesicles isolated from cultures of engineered EDCs. There is also disclosed a method for treating or ameliorating a damaged myocardium in a subject, comprising administering the engineered EDCs or the extracellular vesicles isolated from cultures of engineered EDCs to the damaged myocardium of the subject.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: October 24, 2023
    Assignees: Ottawa Heart Institute Research Corporation, L'Institut de Cardiologie de Montréal
    Inventors: Patrick Vigneault, Darryl Davis, Stanley Nattel, Sandrine Parent
  • ENGINEERED STEM CELLS AND CELLULAR PRODUCTS PRODUCED AND SECRETED BY SUCH CELLS, METHODS OF PREPARING, AND USES THEREOF
    Publication number: 20200172871
    Abstract: There is disclosed a cardiac explant-derived stem cell (EDC), the cell comprising a gene encoding an intermediate-conductance Ca2+-activated K+ channel, and wherein the gene causes an overexpression of the intermediate-conductance Ca2+-activated K+ channel, and methods of producing same. There is also disclosed a method of producing engineered EDCs having a modulated bioelectric property, the method comprising: obtaining EDCs; introducing a KCNN4 gene into the EDCs to increase the expression of KCa3.1 channels, to produce engineered EDCs. There is also disclosed a composition for treating or ameliorating a damaged myocardium in a subject, the composition comprising extracellular vesicles isolated from cultures of engineered EDCs. There is also disclosed a method for treating or ameliorating a damaged myocardium in a subject, comprising administering the engineered EDCs or the extracellular vesicles isolated from cultures of engineered EDCs to the damaged myocardium of the subject.
    Type: Application
    Filed: November 8, 2019
    Publication date: June 4, 2020
    Inventors: Patrick VIGNEAULT, Darryl DAVIS, Stanley NATTEL, Sandrine PARENT